Noven Presents Pre-clinical Study Data at AAPS Annual Meeting

-- Noven Pharmaceuticals, Inc. (NASDAQ:NOVN) announced today that the company presented the results of five pre-clinical transdermal research projects at the recent 2004 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition. The full text of these presentations is available on Noven’s website at under "Research/Scientific Publications."

"Noven continues to advance a very active pre-clinical development program," said Juan Mantelle, Noven’s Vice President and Chief Technical Officer. "The AAPS presentations represent just a small portion of our development efforts, and reflect our commitment to advancing the science of transdermal drug delivery."

At the AAPS meeting, David Kanios, Noven's Director – Research & Development, presented “In-Vitro Permeation and Delivery Profile from Transdermal Drug Delivery System Utilizing Varying Ratios of Hard and Soft Monomers Comprising Acrylic Adhesives.”

David Houze, Noven Senior Research Scientist, presented the results of a study entitled “Enhanced Transdermal Permeation Performance Utilizing Pro-drugs of Testosterone.”

Rod L. Hartwig, Noven Research Scientist, presented “Acrylic Polymer Backing Films for Controlling In-Vitro Permeation and Delivery Profile of Estradiol from Transdermal Drug Delivery Systems.”

Viet T. Nguyen, Noven Senior Scientist – Product Development, presented “Effect of Backing Materials on Clonidine Transdermal Drug Delivery” and “Release Profile of Transdermal Drug Delivery System Utilizing Clonidine Crystals of Varying Particle Size.”

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leading developer of advanced transdermal drug delivery technologies and prescription transdermal products. Noven’s prescription patches are approved in over 30 countries, and a range of new patches are being developed in collaboration with Novartis Pharma AG, Shire Pharmaceuticals Group plc, P&G Pharmaceuticals, Endo Pharmaceuticals Inc. and others. Noven is committed to expanding the universe of available transdermal therapies for the benefit of patients, partners and shareholders. See for additional information.

Investors & Media:
Joseph C. Jones
Vice President – Corporate Affairs

Business Development & Licensing
Pavan Handa
Vice President – Business Development